A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Gov. Josh Shapiro on Tuesday delivered a $51.5 billion budget proposal for the 2025-2026 fiscal year that he touted as a plan ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

The company's newly restructured I&AF segment, which provides advisory and technical services to various industries, has been ...

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the world's largest association of facial plastic and reconstructive surgeons, has released its highly anticipated 2024 ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...